DBT inhibitors encompass a diverse range of compounds primarily characterized by their ability to modulate the function of the Doubletime (DBT) protein. DBT, known for its significant role in the regulation of circadian rhythms, operates predominantly through kinase activities, making kinase inhibition a primary method of its modulation. Compounds such as Staurosporine and Bisindolylmaleimide I exemplify this approach by directly targeting the kinase activity of DBT, thereby influencing its regulatory functions.
Apart from direct kinase inhibition, DBT inhibitors also include compounds that indirectly affect DBT's role in various signaling pathways. This indirect inhibition is crucial because DBT does not operate in isolation but is part of larger cellular signaling networks. Compounds like H-89 and U0126, which inhibit protein kinase A and MEK respectively, demonstrate this method. By targeting these enzymes, these inhibitors can modulate the phosphorylation cascade that DBT is a part of, thus influencing its activity. Similarly, PI3K inhibitors such as LY 294002 and Wortmannin, and the mTOR inhibitor Rapamycin, demonstrate how the inhibition of other components in the signaling pathways can indirectly impact DBT's function.
In addition to these, inhibitors targeting other kinases like p38 MAP kinase (SB 203580), JNK (SP600125), c-Raf (ZM 336372), and ERK (SL-327) also form part of this chemical class. These compounds, though not directly interacting with DBT, have the potential to modulate its activity by altering the signaling landscape within which DBT operates. The diversity of these inhibitors, ranging from broad-spectrum kinase inhibitors to more targeted compounds, highlights the complexity of the signaling pathways DBT is involved in and the various points at which these pathways can be modulated to influence DBT's activity. Overall, through both direct kinase inhibition and indirect modulation of related signaling pathways, these compounds exhibit the potential to influence DBT's function in significant ways.
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A potent kinase inhibitor that can inhibit DBT by targeting its kinase activity. | ||||||
H-89 dihydrochloride | 130964-39-5 | sc-3537 sc-3537A | 1 mg 10 mg | $92.00 $182.00 | 71 | |
A protein kinase A inhibitor that may indirectly affect DBT's role in phosphorylation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor that could disrupt signaling pathways DBT is involved in. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Another PI3K inhibitor, potentially affecting DBT's role in cellular signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Inhibits mTOR, which may interact with pathways involving DBT. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAP kinase inhibitor, potentially affecting DBT's downstream effects. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
Inhibits MEK, which is upstream of some pathways DBT is involved in. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor, potentially affecting signaling pathways related to DBT. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
Another MEK inhibitor, potentially altering DBT's functional pathways. | ||||||
ZM 336372 | 208260-29-1 | sc-202857 | 1 mg | $46.00 | 2 | |
A c-Raf inhibitor, which might affect DBT's role in certain signaling pathways. |